54 research outputs found
Preparation of Silver Nanoparticles by Chemical Reaction Method at Different Reaction Temperatures and the Study of their Antibacterial Activity
It is found silver nanoparticles have strong antibacterial activity due to use in medical applications. It can be tuned antibacterial activity through control the shape and size of the synthesized silver nanoparticles. This article, silver nanoparticles were produced as different sizes at different reaction temperatures by chemical reaction method. Morphology and structure have been characterized by Scanning Electron Microscopy (SEM), Transmission Electron Microscopy (TEM), X-ray diffraction (XRD) and UV-Visible Spectroscopy. Results indicate that silver nanoparticles have different sizes in range of (30- 97.26 nm). Additionally, antibacterial activity test against the pathogens, namely Escherichia colis hows effective inhibitory activity
Molecular characterization of a Bean yellow mosaic virus isolate from Syria
Bean yellow mosaic virus (BYMV, genus Potyvirus, family Potyviridae) was studied by comparing sequences from the coat protein (CP) gene of a Syrian isolate with sequences of six other isolates from the NCBI database. A homology tree of the CP sequences was developed using DNAMAN Software. BYMV isolates were grouped into two clusters of which the first comprised the Syrian isolate together with the Indian, Australian and Japanese isolates, and the second the BYMV isolates from China, the Netherlands and the USA. Moreover, the homology tree showed that the Syrian isolate was very close to the Indian one, with 99% homology
A protocol developing, disseminating and implementing a core outcome set for infertility.
STUDY QUESTIONS: We aim to produce, disseminate and implement a core outcome set for future infertility research.
WHAT IS KNOWN ALREADY: Randomized controlled trials (RCTs) evaluating infertility treatments have reported many different outcomes, which are often defined and measured in different ways. Such variation contributes to an inability to compare, contrast and combine results of individual RCTs. The development of a core outcome set will ensure outcomes important to key stakeholders are consistently collected and reported across future infertility research.
STUDY DESIGN SIZE DURATION: This is a consensus study using the modified Delphi method. All stakeholders, including healthcare professionals, allied healthcare professionals, researchers and people with lived experience of infertility will be invited to participate.
PARTICIPANTS/MATERIALS SETTING METHODS: An international steering group, including people with lived experience of infertility, healthcare professionals, allied healthcare professionals and researchers, has been formed to guide the development of this core outcome set. Potential core outcomes have been identified through a comprehensive literature review of RCTs evaluating treatments for infertility and will be entered into a modified Delphi method. Participants will be asked to score potential core outcomes on a nine-point Likert scale anchored between one (not important) and nine (critical). Repeated reflection and rescoring should promote convergence towards consensus 'core' outcomes. We will establish standardized definitions and recommend high-quality measurement instruments for individual core outcomes.
STUDY FUNDING/COMPETING INTERESTS: This project is funded by the Royal Society of New Zealand Catalyst Fund (3712235). BWM reports consultancy fees from Guerbet, Merck, and ObsEva. R.S.L. reports consultancy fees from Abbvie, Bayer, Fractyl and Ogeda and research sponsorship from Ferring. S.B. is the Editor-in-Chief of Human Reproduction Open. The remaining authors declare no competing interests
Developing a core outcome set for future infertility research: an international consensus development study.
STUDY QUESTION: Can a core outcome set to standardize outcome selection, collection, and reporting across future infertility research be developed?
SUMMARY ANSWER: A minimum data set, known as a core outcome set, has been developed for randomized controlled trials (RCT) and systematic reviews evaluating potential treatments for infertility.
WHAT IS KNOWN ALREADY: Complex issues, including a failure to consider the perspectives of people with fertility problems when selecting outcomes, variations in outcome definitions, and the selective reporting of outcomes on the basis of statistical analysis, make the results of infertility research difficult to interpret.
STUDY DESIGN, SIZE, DURATION: A three-round Delphi survey (372 participants from 41 countries) and consensus development workshop (30 participants from 27 countries).
PARTICIPANTS/MATERIALS, SETTING, METHODS: Healthcare professionals, researchers, and people with fertility problems were brought together in an open and transparent process using formal consensus science methods.
MAIN RESULTS AND THE ROLE OF CHANCE: The core outcome set consists of: viable intrauterine pregnancy confirmed by ultrasound (accounting for singleton, twin, and higher multiple pregnancy); pregnancy loss (accounting for ectopic pregnancy, miscarriage, stillbirth, and termination of pregnancy); live birth; gestational age at delivery; birthweight; neonatal mortality; and major congenital anomaly. Time to pregnancy leading to live birth should be reported when applicable.
LIMITATIONS, REASONS FOR CAUTION: We used consensus development methods which have inherent limitations, including the representativeness of the participant sample, Delphi survey attrition, and an arbitrary consensus threshold.
WIDER IMPLICATIONS OF THE FINDINGS: Embedding the core outcome set within RCTs and systematic reviews should ensure the comprehensive selection, collection, and reporting of core outcomes. Research funding bodies, the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) statement, and over 80 specialty journals, including the Cochrane Gynaecology and Fertility Group, Ferility and Sterility, and Human Reproduction, have committed to implementing this core outcome set.
STUDY FUNDING/COMPETING INTEREST(S): This research was funded by the Catalyst Fund, Royal Society of New Zealand, Auckland Medical Research Fund, and Maurice and Phyllis Paykel Trust. Siladitya Bhattacharya reports being the Editor-in-Chief of Human Reproduction Open and an editor of the Cochrane Gynaecology and Fertility group. Hans Evers reports being the Editor Emeritus of Human Reproduction. José Knijnenburg reports research sponsorship from Ferring and Theramex. Richard Legro reports consultancy fees from Abbvie, Bayer, Ferring, Fractyl, Insud Pharma and Kindex and research sponsorship from Guerbet and Hass Avocado Board. Ben Mol reports consultancy fees from Guerbet, iGenomix, Merck, Merck KGaA and ObsEva. Craig Niederberger reports being the Co Editor-in-Chief of Fertility and Sterility and Section Editor of the Journal of Urology, research sponsorship from Ferring, and retains a financial interest in NexHand. Annika Strandell reports consultancy fees from Guerbet. Ernest Ng reports research sponsorship from Merck. Lan Vuong reports consultancy and conference fees from Ferring, Merck and Merck Sharp and Dohme. The remaining authors declare no competing interests in relation to the work presented. All authors have completed the disclosure form.
TRIAL REGISTRATION NUMBER: Core Outcome Measures in Effectiveness Trials Initiative:Â 1023
Developing a minimum data set, known as a core outcome set, for future infertility research
Background: Complex issues, including a failure to consider the perspectives of people with fertility problems when selecting outcomes, variations in outcome definitions, and outcome reporting bias, make the results of infertility research difficult to interpret.
Objectives: To develop a core outcome set to standardise outcome selection, collection, and reporting across future randomized controlled trials and systematic reviews evaluating potential treatments for infertility.
Methods: Healthcare professionals, researchers, and people with fertility problems were brought together in an open and transparent process using formal consensus science methods including a three-round Delphi survey (372 participants from 41 countries) and consensus development workshop (30 participants from 27 countries) (1).
Results: The core outcome set consists of: (1) viable intrauterine pregnancy confirmed by ultrasound (accounting for singleton, twin, and higher multiple pregnancies); (2) pregnancy loss (accounting for ectopic pregnancy, miscarriage, stillbirth, and termination of pregnancy); (3) live birth; (4) gestational age at delivery; (5) birth weight; (6) neonatal mortality; and (7) major congenital anomaly. Time to pregnancy leading to live birth should be reported when applicable.
Conclusions: Embedding the core outcome set within randomized controlled trials and systematic reviews should ensure the comprehensive selection, collection, and reporting of core outcomes. Research funding bodies, the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) statement, and over 80 specialty journals, including Cochrane Gynaecology and Fertility Group, Fertility and Sterility, and Human Reproduction, have committed to implementing this core outcome set
Standardizing definitions and reporting guidelines for the infertility core outcome set: an international consensus development studyâ  âĄ.
STUDY QUESTION: Can consensus definitions for the core outcome set for infertility be identified in order to recommend a standardized approach to reporting?
SUMMARY ANSWER: Consensus definitions for individual core outcomes, contextual statements and a standardized reporting table have been developed.
WHAT IS KNOWN ALREADY: Different definitions exist for individual core outcomes for infertility. This variation increases the opportunities for researchers to engage with selective outcome reporting, which undermines secondary research and compromises clinical practice guideline development.
STUDY DESIGN, SIZE, DURATION: Potential definitions were identified by a systematic review of definition development initiatives and clinical practice guidelines and by reviewing Cochrane Gynaecology and Fertility Group guidelines. These definitions were discussed in a face-to-face consensus development meeting, which agreed consensus definitions. A standardized approach to reporting was also developed as part of the process.
PARTICIPANTS/MATERIALS, SETTING, METHODS: Healthcare professionals, researchers and people with fertility problems were brought together in an open and transparent process using formal consensus development methods.
MAIN RESULTS AND THE ROLE OF CHANCE: Forty-four potential definitions were inventoried across four definition development initiatives, including the Harbin Consensus Conference Workshop Group and International Committee for Monitoring Assisted Reproductive Technologies, 12 clinical practice guidelines and Cochrane Gynaecology and Fertility Group guidelines. Twenty-seven participants, from 11 countries, contributed to the consensus development meeting. Consensus definitions were successfully developed for all core outcomes. Specific recommendations were made to improve reporting.
LIMITATIONS, REASONS FOR CAUTION: We used consensus development methods, which have inherent limitations. There was limited representation from low- and middle-income countries.
WIDER IMPLICATIONS OF THE FINDINGS: A minimum data set should assist researchers in populating protocols, case report forms and other data collection tools. The generic reporting table should provide clear guidance to researchers and improve the reporting of their results within journal publications and conference presentations. Research funding bodies, the Standard Protocol Items: Recommendations for Interventional Trials statement, and over 80 specialty journals have committed to implementing this core outcome set.
STUDY FUNDING/COMPETING INTEREST(S): This research was funded by the Catalyst Fund, Royal Society of New Zealand, Auckland Medical Research Fund and Maurice and Phyllis Paykel Trust. Siladitya Bhattacharya reports being the Editor-in-Chief of Human Reproduction Open and an editor of the Cochrane Gynaecology and Fertility Group. J.L.H.E. reports being the Editor Emeritus of Human Reproduction. R.S.L. reports consultancy fees from Abbvie, Bayer, Ferring, Fractyl, Insud Pharma and Kindex and research sponsorship from Guerbet and Hass Avocado Board. B.W.M. reports consultancy fees from Guerbet, iGenomix, Merck, Merck KGaA and ObsEva. C.N. reports being the Editor-in-Chief of Fertility and Sterility and Section Editor of the Journal of Urology, research sponsorship from Ferring, and a financial interest in NexHand. E.H.Y.N. reports research sponsorship from Merck. A.S. reports consultancy fees from Guerbet. J.W. reports being a statistical editor for the Cochrane Gynaecology and Fertility Group. A.V. reports that he is a Statistical Editor of the Cochrane Gynaecology & Fertility Review Group and of the journal Reproduction. His employing institution has received payment from Human Fertilisation and Embryology Authority for his advice on review of research evidence to inform their 'traffic light' system for infertility treatment 'add-ons'. N.L.V. reports consultancy and conference fees from Ferring, Merck and Merck Sharp and Dohme. The remaining authors declare no competing interests in relation to the work presented. All authors have completed the disclosure form.
TRIAL REGISTRATION NUMBER: Core Outcome Measures in Effectiveness Trials Initiative: 1023
Perfil proteico de tilĂĄpia nilĂłtica chitralada (Oreochromis niloticus), submetida ao estresse crĂŽnico por hipĂłxia
Endovascular management of postpartum hemorrhage of placental origin
Aim: To evaluate the potential role, efficacy, and complications of endovascular management of postpartum hemorrhage induced by variable placental abnormalities.
Materials and methods: Ten patients with placental abnormalities underwent pelvic arterial embolization in Assiut University Hospital, because of postpartum hemorrhage. Placental abnormalities were; retained placenta (n = 4), placenta accrete vera (n = 1), placenta increta (n = 2), placenta percreta (n = 1), and choriocarcinoma (n = 2). Only three patients were embolized on emergency bases, while the other 7 patients were scheduled for embolization.
Results: The mean hemoglobin level before embolization was 6Â g/dL (range: 4.5â8Â g/dL). Severe coagulation disorders were present in one patient. Postembolization pelvic angiogram showed total devascularization of the pathological arteries in 7(70%) patients, and subtotal devascularization in 3(30%) patients. The clinical success is 100%.
Conclusion: Whatever the placental disease, pelvic embolization with long-lasting embolizing agents is very effective and safe treatment of associated postpartum hemorrhage
Tubulocystic renal cell carcinoma, a rare tumor entity: Review of literature and report of a case
Tubulocystic renal carcinoma is a recently described neoplasm of low grade malignancy which was not included in the last WHO 2004 classification. The tumor is extremely rare with less than one hundred cases reported to date. In this article, the literature about that rare renal neoplasm is reviewed and an additional case is reported
Simulation of Crevice and Pitting Corrosion Using the Orthogonal Collocation Method
Two dangerous forms of localized corrosion are pitting and crevice corrosion. In pitting corrosion, pits are formed as a result of differences in oxygen and ion concentration at the base of a pit compared with the surface. Crevice corrosion occurs at inaccessible locations deficient in oxygen. Elec- trochemically, both pitting and crevice corrosion may be considered equivalent. A variety of steady-state and transient models have been developed to simulate the different stages of pitting and crevice in a variety of metals. Numerical solutions have been obtained for the modeling of corrosion cells. A theoretical model simulating the propagation stage of an established pit or crevice has been developed recently. This model considers the steady state of the solution chemistry and electrochemistry within active and passive cavities, and uses the method of finite elements to solve the complex nonlinear set of mass conservation equations describing the system. In the present work, the method of orthogonal collocation is used for the solution of the steady state describing equation of this model. This results in reducing the dimensionality of the non-linear equations to be solved. Numerical results are presented to show the good performance of the solution algorithm. Only two collocation points are needed to solve the above mentioned model
- âŠ